AVITA Medical, Inc. (RCEL) Misses Q3 EPS by 20c ; Offers Guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q3 EPS of ($0.46), $0.20 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $19.24 million.

GUIDANCE:

AVITA Medical, Inc. sees FY2025 revenue of $70-74 million, versus the consensus of $93.83 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• InMed Pharmaceuticals gets Nasdaq equity deficiency notice
• RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)